{
    "clinical_study": {
        "@rank": "50376", 
        "arm_group": [
            {
                "arm_group_label": "E2022- Tape Formulation", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Matching Placebo E2022", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching Placebo"
            }, 
            {
                "arm_group_label": "E2022- New Formulation", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo E2022- New Formulation", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matching Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and pharmacokinetics of new patch\n      formulation (tape) of E2022 by conducting patch test."
        }, 
        "brief_title": "A Phase 1 Comparative Study of E2022 Current and New Patch Formulations", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n          1. Non-smoker or not smoking for 4 weeks or longer before study treatment\n\n          2. BMI at screening is greater than or equal to 18.5 kg/m2 or less than 25.0 kg/m2\n\n          3. With written informed consent\n\n          4. Given full explanation of this study and is willing to and able to comply with study\n             requirements.\n\n        Exclusion criteria\n\n        (Cohort 1 and 2):\n\n          1. Have a disorder which affects the evaluation of study drug such as psychiatric,\n             gastrointestinal, hepatic, renal, respiratory, endocrinological, hematological,\n             neurological, or cardiovascular system, or congenital metabolic abnormality\n\n          2. Have a clinically significant abnormality or organ dysfunction\n\n          3. Have a history of allergy to drug or food requiring medical treatment or seasonal\n             allergy at screening\n\n          4. Have a history or complication of contact dermatitis or atopic dermatitis\n\n          5. Have hairy back or have shaved within 4 weeks before study treatment\n\n          6. Have a skin disease (e.g., eczema, dermatitis, dyschromatosis), or skin damage (e.g.,\n             injury, scar, or sun burn) which may affect skin assessment\n\n          7. Have a history or suspected to have drug or alcohol dependence, or positive for urine\n             drug screen at baseline or a day before screening\n\n          8. Have had caffeine-containing drink or food, or alcohol within 72 hours before study\n             treatment\n\n          9. Have used liquid product (including cosmetics), or applied patch, tape, or bandage on\n             the back within 4 weeks before study treatment\n\n         10. Had hard exercise at least 5 days a week or a 1-hour or longer hard exercise within 2\n             weeks before study treatment\n\n        (Only Cohort 2):\n\n          1. Meet QTc of greater than 450 milliseconds at screening or immediately before study\n             treatment\n\n          2. Had nutrients, herb preparations (e.g. oriental medicine), other food or drink (e.g.,\n             grapefruit-containing juice) which may affect the activity of drug-metabolizing\n             enzyme or transporter within 2 weeks before study treatment\n\n          3. Had St. John's Wort-containing preparation within 4 weeks before Period 1 application"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "39 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02042729", 
            "org_study_id": "E2022-J081-006"
        }, 
        "intervention": [
            {
                "arm_group_label": "E2022- Tape Formulation", 
                "description": "Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.\nCohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.", 
                "intervention_name": "E2022- Current Formula Tape", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "E2022- New Formulation", 
                "description": "Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.\nCohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.", 
                "intervention_name": "E2022- New Formula Tape", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Matching Placebo E2022", 
                "intervention_name": "E2022 Matching Placebo- Current Formula Tape", 
                "intervention_type": "Drug", 
                "other_name": "Cohort I: E2022 Matching Placebo current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test."
            }, 
            {
                "arm_group_label": "Placebo E2022- New Formulation", 
                "intervention_name": "E2022 Matching Placebo- New Formula Tape", 
                "intervention_type": "Drug", 
                "other_name": "Cohort I: E2022 Matching Placebo new formula tape administered on a skin application site and evaluated for"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "volunteer", 
        "lastchanged_date": "February 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fukuoka", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 1 Comparative Study of E2022 Current and New Patch Formulations", 
        "overall_official": {
            "affiliation": "Eisai Co., Ltd.", 
            "last_name": "Hidetaka Hiramatsu", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "10 days (Cohort I) and 40 days (Cohort II)"
            }, 
            {
                "measure": "Frequency of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "10 days (Cohort I) and 40 days (Cohort II)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02042729"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic Parameter: Cmax", 
                "safety_issue": "No", 
                "time_frame": "40 days (Cohort II)"
            }, 
            {
                "measure": "Pharmacokinetic Parameter: Tmax", 
                "safety_issue": "No", 
                "time_frame": "40 days (Cohort II)"
            }, 
            {
                "measure": "Pharmacokinetic Parameter: AUC", 
                "safety_issue": "No", 
                "time_frame": "40 days (Cohort II)"
            }
        ], 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}